Kymera Therapeutics Inc (KYMR) Insider Trading
- $64,580,508.56
- $131,097,953.10
- Sept. 17, 2024
- Nello Mainolfi
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
Sept. 17, 2024 | Director | 13,500 | $48.28 | Sell | $651,780.00 | |
Aug. 26, 2024 | Director | 5,000 | $49.10 | Sell | $245,500.00 | |
July 16, 2024 | Insider | 23,145 | $45.81 | Sell | $1,060,272.45 | |
July 9, 2024 | Director | 453,960 | $38.21 | Sell | $17,345,811.60 | |
June 12, 2024 | Director | 16,740 | $35.45 | Sell | $593,433.00 | |
June 7, 2024 | Director | 8,500 | $32.99 | Sell | $280,415.00 | |
March 15, 2024 | Director | 71,764 | $40.46 | Sell | $2,903,571.44 | |
March 13, 2024 | Major Shareholder | 115,090 | $42.23 | Sell | $4,860,250.70 | |
March 13, 2024 | Director | 139,255 | $42.23 | Sell | $5,880,738.65 | |
March 11, 2024 | Director | 51,184 | $42.85 | Sell | $2,193,234.40 | |
March 11, 2024 | Major Shareholder | 42,302 | $42.85 | Sell | $1,812,640.70 | |
March 4, 2024 | CFO | 3,934 | $41.86 | Sell | $164,677.24 | |
Feb. 21, 2024 | Director | 4,385 | $39.05 | Sell | $171,234.25 | |
Feb. 9, 2024 | Insider | 46,137 | $35.50 | Sell | $1,637,863.50 | |
Jan. 23, 2024 | Director | 10,000 | $30.05 | Sell | $300,500.00 | |
Jan. 4, 2024 | Insider | 3,295 | $22.58 | Sell | $74,401.10 | |
Nov. 2, 2023 | Director | 216,406 | $11.64 | Buy | $2,518,965.84 | |
March 2, 2023 | CFO | 1,370 | $31.00 | Sell | $42,470.00 | |
Jan. 11, 2023 | Director | 22,110 | $29.89 | Buy | $660,867.90 | |
Jan. 11, 2023 | Major Shareholder | 21,683 | $29.96 | Sell | $649,622.68 | |
Dec. 14, 2022 | Major Shareholder | 296,077 | $31.37 | Sell | $9,287,935.49 | |
Dec. 14, 2022 | Director | 378,966 | $31.37 | Sell | $11,888,163.42 | |
Nov. 2, 2022 | Major Shareholder | 96,581 | $30.02 | Sell | $2,899,361.62 | |
Nov. 2, 2022 | Director | 123,619 | $30.02 | Sell | $3,711,042.38 | |
Oct. 31, 2022 | Major Shareholder | 94,239 | $30.23 | Sell | $2,848,844.97 | |
Oct. 31, 2022 | Director | 120,622 | $30.23 | Sell | $3,646,403.06 | |
Oct. 28, 2022 | Major Shareholder | 71,135 | $30.00 | Sell | $2,134,050.00 | |
Oct. 28, 2022 | Director | 91,050 | $30.00 | Sell | $2,731,500.00 | |
Aug. 22, 2022 | Director | 545,525 | $26.00 | Buy | $14,183,650.00 | |
May 26, 2022 | Director | 224,057 | $14.21 | Buy | $3,183,849.97 | |
May 20, 2022 | Director | 10,100 | $14.00 | Buy | $141,400.00 | |
May 5, 2022 | Director | 150,000 | $19.60 | Buy | $2,940,000.00 | |
Jan. 31, 2022 | Director | 34,408 | $40.70 | Buy | $1,400,405.60 | |
Jan. 27, 2022 | Director | 95,901 | $38.33 | Buy | $3,675,885.33 | |
Jan. 24, 2022 | Director | 272,767 | $37.76 | Buy | $10,299,681.92 | |
Jan. 12, 2022 | CEO | 8,612 | $52.08 | Sell | $448,512.96 | |
Jan. 12, 2022 | CFO | 15,000 | $51.85 | Sell | $777,750.00 | |
Jan. 10, 2022 | CEO | 22,465 | $53.26 | Sell | $1,196,485.90 | |
Dec. 3, 2021 | CFO | 10,000 | $53.56 | Sell | $535,600.00 | |
Nov. 2, 2021 | Insider | 14,996 | $63.22 | Sell | $948,047.12 | |
Oct. 11, 2021 | CEO | 6,456 | $53.68 | Sell | $346,558.08 | |
Oct. 8, 2021 | CEO | 41,544 | $56.76 | Sell | $2,358,037.44 | |
Sept. 3, 2021 | CFO | 10,000 | $60.12 | Sell | $601,200.00 | |
Aug. 27, 2021 | Insider | 33,779 | $60.12 | Sell | $2,030,793.48 | |
Aug. 17, 2021 | Insider | 54,000 | $50.37 | Sell | $2,719,980.00 | |
Aug. 11, 2021 | Director | 242,133 | $61.00 | Sell | $14,770,113.00 | |
Aug. 4, 2021 | CEO | 1,037 | $60.03 | Sell | $62,251.11 | |
Aug. 2, 2021 | CEO | 23,456 | $60.30 | Sell | $1,414,396.80 | |
July 30, 2021 | CEO | 6,279 | $60.07 | Sell | $377,179.53 | |
July 28, 2021 | CEO | 3,864 | $60.15 | Sell | $232,419.60 |
Insiders are both buying and selling Kymera Therapeutics Inc stock.
The insider traders at Kymera Therapeutics Inc are: Nello Mainolfi, Bruce Booth, Bvf Partners L P/Il, Bruce N Jacobs, Venture Fund X L.P. Atlas, Jared Gollob, Jeffrey W. Albers, Richard Chesworth, Joanna Horobin, Ellen Chiniara, Pamela Esposito, and Bruce N. Jacobs
The most active insider trader at Kymera Therapeutics Inc is Nello Mainolfi with 19 trades.
Bruce Booth has sold the most Kymera Therapeutics Inc stock with a total value of $95,968,097.55.
Bvf Partners L P/Il has bought the most Kymera Therapeutics Inc stock with a total value of $67,099,474.40.
The most recent insider trade for Kymera Therapeutics Inc was on Sept. 17, 2024.
The single biggest insider buy for Kymera Therapeutics Inc was from Bvf Partners L P/Il with a total value of $25,575,802.00 on July 1, 2021.
The single biggest insider sell for Kymera Therapeutics Inc was from Bruce Booth with a total value of $17,345,811.60 on July 9, 2024.